Pension firm: Coloplast's secret tax report could cost skilled employees

Coloplast is missing out on an advantage when recruiting and retaining skilled employees when it does not present its international tax payments, says Danish pension fund Akademikerpension, stating that transparency and trust are crucial in the competition over the best employees. (Corrected)

Photo: Coloplast / PR

(Correction: An earlier version of the article stated that Akademikerpension had assessed that Coloplast could be hurt in the competition to recruit the best employees if it did not report on its tax payments on a country-by-country basis. The pension firm emphasizes that this is only the case over time if the medtech company's competition becomes more transparent, and adds that Coloplast is not suffering any recruitment losses in its current situation. The article also previously stated that Akademikerpension had attempted to push Coloplast into publicizing its national tax payments for over a year. This has been corrected, now reporting that Akademikerpension inquired whether there were any obstacles for doing so).

A year ago, Danish pension firm Akademikerpension inquired whether Coloplast knew of any potential obstacles for publicizing its tax payments in all of the countries it operates in. However, the pension firm received no clear answer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs